Abbreviations: BM = bone marrow; HSCT = hematopoietic stem cell transplantation; MAC = myeloablative conditioning; MSD = matched sibling donor; MUD = matched unrelated donor; RIC = reduced intensity conditioning; Tx = transplant.
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option to treat patients with high-risk hematological malignancies. 1 Transplant procedures have been changed over the years with the possibility of performing transplants from alternative donors, and using reduced intensity conditioning (RIC) regimens. However, transplant-related mortality and disease recurrence remain major obstacles to HSCT success. 2 In patients surviving HSCT, long-term complications, particularly chronic GvHD (cGvHD), are associated with high morbidity and impaired quality of life. 3 Clinical and biological manifestations of cGvHD 4 have a wide range of severity and could involve many tissues and organs including often oral mucosa, eyes, skin, gastrointestinal tract, liver and bone marrow (BM). Incidence of severe chronic GvHD, previously indicated as extensive, affects~30-70% of HSCT survivors. 5, 6 For clinical research on HSCT, the most commonly used end point is disease-free survival (DFS), which reflects a status of survival without relapse or progression. However, the main pitfall of such end point is that it disregards events like severe GvHD. Several publications on retrospective and registry data comparing transplant modalities (according to the type of donor, stem cell source or conditioning intensity) showed major differences in the incidence of chronic GvHD. 7 Therefore, a composite end point that combines both DFS and GvHD is needed. Holtan et al. recently proposed use of GvHD-free, relapse-free survival (GRFS) for HSCT outcomes. 8 This end point might reflect more precisely health status post transplantation and better quality of life, and has been defined as being alive with neither grade III-IV acute GvHD (aGVHD) nor cGvHD requiring immunosuppressive treatment (IST), and without disease recurrence or death from any cause during the first 1 year after HSCT. The incidence of cGvHD requiring systemic treatment ranges from 30 to 40%, by the National Institute of Health criteria. However, systemic treatment of cGvHD does not always reflect the severity of cGvHD as it could be indicated for patients with moderate disease. 9 cGvHD is an event which fluctuates with time, and the initiation of IST may not be a good indicator of the impact of this disabling disease on patients' long-term outcome and daily life.
For more than 20 years, registry-based studies allowed evaluation of the role of HSCT and comparison of different transplant modalities in defined populations addressing risk factors and criteria for donor choice. However, information on start of IST is not routinely collected by the major HSCT registries. Therefore, we conceived a 'refined' GRFS for registry-based studies. GRFS events were defined according to the original report 8 as the first event among grade III-IV aGvHD, severe cGvHD, relapse and death. Then, differently from the GRFS definition by Holtan, cGvHD requiring systemic treatment was replaced by the occurrence of severe cGvHD. We aimed to validate this new end point looking to the correlation with Karnofsky status at last follow-up.
Adults transplanted for AML in first or second CR (CR1 or CR2), undergoing HSCT from a matched sibling donor (MSD) or matched unrelated donor (MUD) in the European Society for Blood and Marrow Transplantation centers from 2000 to 2014 were selected. Patients receiving myeloablative conditioning (MAC) or RIC regimen were included. 10 Other end points were overall survival (OS), leukemia-free survival (LFS), incidence of relapse, non-relapse mortality (NRM), aGvHD and cGvHD. All probabilities were calculated from the date of transplant. Acute GvHD and cGvHD were graded according to the previously published criteria. 9, 11 Probabilities of GRFS, LFS and OS were calculated using the Kaplan-Meier estimates. 12 Cumulative incidence functions were used to estimate relapse incidence (RI) and NRM in a competing risks setting, as death and relapse compete with each other. To study aGvHD and cGvHD, we considered relapse and death to be competing events.
We analyzed 20 937 patients with AML (Table 1) , the median age at HSCT was 48 years (range 18-80) and the median year of HSCT was 2009 (range 2000-2014). Seventy-nine percent of patients underwent HSCT in CR1 and 21% in CR2. Donors were MSD in 55% and MUD in 45% of patients. Stem cell source was BM and PBSC in 18% and 82% of cases, respectively. Conditioning regimen was MAC in 61% of the patients and RIC in 39%. With a median follow-up of 36 months (range 3-185), the probability of 3-year OS and LFS was 58.7% (95% confidence interval (CI) 57.9-59.4) and 53.4% (95% CI 52.7-54.2), respectively ( Figure 1 ). Cumulative incidence of relapse, NRM, grade III-IV aGvHD and severe cGvHD were 27.4% (95% CI 26.7-28.1), 19.2% (95% CI 16.6-19.7), 8.3% (95% CI 7.9-8.7) and 29% (95% CI 28.4-29.7), respectively. The probability of 3-year refined GRFS was 40.1% (95% CI 39.3-40.8; Figure 1 ). Considering the GRFS events, relapse accounted for the greater proportion (40%), severe cGvHD for 26%, NRM for 20% and grade III-IV aGvHD for 14%.
Holtan et al. 8 reported a 1-year GRFS of 31% in more than 900 patients transplanted with MSD, MUD or single or double cord blood transplantation, at University of Minnesota. There are some differences between the two studies. We analyzed a large cohort of adults transplanted for AML in CR1 and CR2 only, in order to avoid the possible confounding factor of the biology of the hematological malignancies mainly on the relapse and transplantrelated toxicities. GRFS was reported at 3 years, as it has been showed that 20% of the patients remains at risk of relapse after 2 years post HSCT, 13 and also cGvHD could occur later than the first 12 months after HSCT, especially using PBSC as stem cell source and in the RIC setting.
Importantly, we found an association between a Karnofsky status of 100% at the last follow-up and GRFS (P o 0.001) and notably, for patients with severe cGvHD, alive without disease recurrence at last follow-up, GvHD remained severe in 86% of cases, while it was limited in 14%.
The impact of cGvHD has already been reported in studies on long-term quality of life after HSCT by Lee et al.
14 who assigned to cGvHD a coefficient of 0.80 for calculation of quality-adjusted life years for cost-effectiveness studies. 15 Our results confirm that refined GRFS is a useful end point to evaluate HSCT outcomes. For registry-based studies, the use of severe cGvHD is a valuable indicator of organ impairment and quality of life. For these types of studies, it could replace the use of cGvHD requiring systemic therapy as event for defining the GRFS. Evaluation of this new end point in homogenous cohort of patients and according to donor type is warranted to address risk factors that may optimize HSCT outcomes.
